Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus rhamnosus 86
- Development stage
- Preclinical
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus rhamnosus 86 is a specific probiotic strain of lactic acid bacteria investigated for its potential anti-obesity and metabolic health benefits. Research indicates that the strain can reduce cholesterol levels and inhibit the differentiation of preadipocytes into mature adipocytes, thereby suppressing fat accumulation. This effect is primarily mediated through the downregulation of key adipogenic and lipogenic transcription factors, including PPARγ, C/EBPα, and SREBP-1c. In vivo studies using high-fat diet-induced obese mouse models have shown that daily oral administration of L. rhamnosus 86 improves serum lipid profiles, reduces the expression of genes related to fat synthesis in white adipose tissue, and helps normalize obesity-related gut microbiota dysbiosis.
- Other names
- L. rhamnosus 86Lacticaseibacillus rhamnosus 86
02
Targets
PPARG (Peroxisome proliferator-activated receptor gamma)CEBPA (CCAAT enhancer-binding protein alpha)SREBP-1 / SREBF1 (SREBP-1)
Beyond the preview
Go deeper on lactobacillus rhamnosus 86.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus rhamnosus 86.